Michael L. Tapper
Lenox Hill Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael L. Tapper.
Annals of Internal Medicine | 1982
Jeffrey B. Greene; Gurdip S. Sidhu; Sharon R. Lewin; Jerome Levine; Henry Masur; Michael S. Simberkoff; Peter Nicholas; Robert C. Good; Susan Zolla-Pazner; Alan A. Pollock; Michael L. Tapper; Robert S. Holzman
Five men developed disseminated infection with Mycobacterium avium-intracellulare. These patients all lived in the New York City area and presented with their illnesses between January 1981 and September 1981; four were homosexual and one was an intravenous drug abuser. Four patients died. All five patients had defects in the cell-mediated immune response. The infections were characterized histopathologically by poor or absent granulomatous tissue reaction. Clinical isolates of M. avium-intracellulare from all five patients agglutinated commonly used antimycobacterial drugs. The spectrum of opportunistic infections among populations of homosexuals and drug abusers should be expanded to include disseminated disease due to M. avium-intracellulare.
Clinical Infectious Diseases | 2009
Scott A. Harper; John S. Bradley; Janet A. Englund; Thomas M. File; Stefan Gravenstein; Frederick G. Hayden; Allison McGeer; Kathleen M. Neuzil; Andrew T. Pavia; Michael L. Tapper; Timothy M. Uyeki; Richard K. Zimmerman
Abstract Un Grupo de Expertos de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América elaboró las guias para el tratamiento de personas infectadas por el virus de la influenza. Estas guias basadas en datos y pruebas cientificas comprenden el diagnóstico, el tratamiento y la quimioprofilaxis con medicamentos antivirales, además de temas relacionados con el control de brotes de influenza estacional (interpandémicas) en ámbitos institucionales. Están destinadas a los médicos de todas las especialidades a cargo de la atención directa de pacientes porque los médicos generales que atienden una gran variedad de casos son los que se enfrentan con la influenza, frecuente en el ámbito comunitario durante la temporada de influenza.
American Journal of Ophthalmology | 1984
William R. Freeman; Chester W. Lerner; Jonathan A. Mines; Roger S. Lash; Alfred J. Nadel; Michael B. Starr; Michael L. Tapper
A prospective evaluation of ophthalmologic findings in 26 patients (25 men and one woman) with the acquired immune deficiency syndrome disclosed that 19 patients had significant ocular abnormalities. These included isolated retinal hemorrhages, cotton-wool spots, cytomegalovirus retinitis, acute retinal necrosis, cranial nerve palsies, and orbital Kaposis sarcoma. Hemorrhages and cotton-wool spots appeared and disappeared spontaneously. Cytomegalovirus retinitis and acute retinal necrosis were progressive and destructive. The fundus findings did not correlate with the patients general clinical status.
Annals of Internal Medicine | 1984
Brian Wong; Jonathan W. M. Gold; Arthur E. Brown; Michael Lange; Richard Fried; Michael H. Grieco; Donna Mildvan; José A. Girón; Michael L. Tapper; Chester W. Lerner; Donald Armstrong
Central-nervous-system toxoplasmosis developed in 7 of 269 patients with the acquired immunodeficiency syndrome reported to the New York City Health Department through July 1982. Focal neurologic abnormalities, mass lesions on computed-tomographic brain scans, lymphocytic cerebrospinal fluid pleocytosis, and detectable IgG antibody to Toxoplasma gondii were common; but IgG titers of 1:1024 or more, IgM antibody to T. gondii, and positive open brain biopsies were uncommon. Serologic findings suggested that the disease resulted from recrudescent rather than primary infection. Four of five patients improved when treated with sulfonamides and pyrimethamine, but 2 had relapses. An aggressive diagnostic approach and sometimes even empiric therapy are warranted when central-nervous-system toxoplasmosis is suspected in a seropositive patient with the acquired immunodeficiency syndrome.
Annals of Internal Medicine | 1982
Henry Masur; Mary Ann Michelis; Gary P. Wormser; Sharon R. Lewin; Jon Gold; Michael L. Tapper; José A. Girón; Chester W. Lerner; Donald Armstrong; Usha Setia; Joel A. Sender; Robert S. Siebken; Peter Nicholas; Zelman Arlen; Shlomo Maayan; Jerome A. Ernst; Frederick P. Siegal; Susanna Cunningham-Rundles
Opportunistic infections and unusual tumors have been reported in an unprecedented outbreak of community-acquired cellular immune deficiency among homosexual and drug-abusing men. We report five women with the same syndrome. The women were residents of metropolitan New York City closely associated with drug abuse either by personal use (our patients) or close sexual contact with an abuser (one patient). One patient was bisexual. All five patients developed Pneumocystis carinii pneumonia as well as combinations of other opportunistic infections including oral candida, disseminated mycobacteria, and ulcerative herpes simplex infections. All patients had marked depression of cellular immune function. Three patients died. The appearance of this syndrome in women has important implications with regard to the epidemiology and etiology of this emerging syndrome.
Annals of Internal Medicine | 1984
Michael L. Tapper; Heidrun Z. Rotterdam; Chester W. Lerner; Kathleen Al'khafaji; Peter A. Seitzman
Excerpt Since 1980, the medical community has seen an epidemic of opportunistic infections and unusual malignancies now known as the acquired immunodeficiency syndrome. In autopsies done on ten pat...
The Lancet | 2006
Christopher A. Ludlam; William G. Powderly; Samuel A. Bozzette; Michael S. Diamond; Marion A. Koerper; Roshni Kulkarni; Bruce Ritchie; Jamie E. Siegel; Peter Simmonds; Samuel L. Stanley; Michael L. Tapper; Mario von Depka
Summary As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell lymphotropic virus. However, emerging pathogens could pose future threats, particularly those with blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better understanding of infectious diseases allows challenges from newly described agents of potential concern in the future to be anticipated, but the processes of zoonotic transmission and genetic selection or modification ensure that plasma-derived products will continue to be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the issue of emerging infectious agents by developing recombinant products that limit the need for human plasma during production. Such recombinant products have extended the safety profile of their predecessors by ensuring that all reagents used for cell culture, purification steps, and stabilisation and storage buffers are completely independent of human plasma.
Infection Control and Hospital Epidemiology | 2005
Edward S. Wong; Mark E. Rupp; Leonard A. Mermel; Trish M. Perl; Suzanne F. Bradley; Keith M. Ramsey; Belinda Ostrowsky; August J. Valenti; John A. Jernigan; Andreas Voss; Michael L. Tapper
Prior to 2004, only two states, Pennsylvania and Illinois, had enacted legislation requiring healthcare facilities to collect nosocomial or healthcare-associated infection (HAI) data intended for public disclosure. In 2004, two additional states, Missouri and Florida, passed disclosure laws. Currently, several other states are considering similar legislation. In California, Senate Bill 1487 requiring hospitals to collect HAI data and report them to the Office of Statewide Health Planning was passed by the legislature, but was not signed into law by Governor Schwarzenegger, effectively vetoing it. The impetus for these laws is complex. Support comes from consumer advocates, who argue that the public has the right to be informed, and from others who view HAI as preventable and hope that public disclosure would provide an incentive to healthcare providers and institutions to improve their care.
Haemophilia | 2006
Michael L. Tapper
Summary. New pathogens and antimicrobial‐resistant forms of older pathogens continue to emerge, some with the potential for rapid, global spread and high morbidity and mortality. Pathogens can emerge either through introduction into a new population or when the interaction with the vector changes; emergence is also influenced by microbiological adaptation and change, global travel patterns, domestic and wild animal contact and other variants in human ecology and behaviour. Quick, decisive action to detect and control novel pathogens, and thereby contain outbreaks and prevent further transmission, is frequently hampered by incomplete or inadequate data about a new or re‐emerging pathogen. Three examples of pathogens that are current causes for human health concern are avian influenza, West Nile virus (WNV) and the severe acute respiratory syndrome (SARS) coronavirus. Pathogens directly or indirectly transmitted by aerosolized droplets, such as avian influenza and SARS, pose considerable containment challenges. Rapid screening tests for other newly described pathogens such as WNV require time for development and may be <100% reliable. The importance of vigilance in the detection and control of newly recognized infectious threats cannot be overstressed. The presence of infectious agents in the blood supply could again have a significant impact on the safe use of both blood and blood‐derived products in the care of patients with haemophilia, as did the human immunodeficiency virus in the 1980s. Emerging pathogens will continue to be a reality requiring the collaborative efforts of public health and individual healthcare providers worldwide to contain outbreaks and prevent transmission.
Haemophilia | 2006
Lori Luchtman-Jones; Leonard A. Valentino; Catherine S. Manno; Geoffrey A. Allen; Morey A. Blinder; Lisa N. Boggio; Clark Brown; Alan R. Cohen; Kathy Fu; Michael Jeng; Nathan Kobrinsky; Eric H. Kraut; Roshni Kulkarni; Jeanne M. Lusher; Prasad Mathew; Dana C. Matthews; Steven W. Pipe; Doris Quon; Ashok Raj; Jagadeesh Ramdas; Hernan Sabio; Lance Sieger; Michael L. Tapper; David Ungar; Brian Wickland
Summary. The long‐term prophylactic administration of clotting factor concentrate in patients with haemophilia reduces bleeding events, slows joint deterioration, and improves quality of life. Prophylaxis can also be effective when used short‐term to prevent or reduce bleeding associated with trauma, surgery, and athletic activities. While clinical trials are needed to establish the optimal length of prophylaxis following injury, several weeks and possibly months of treatment may be needed. Discontinuing therapy prematurely can result in rebleeding in the injured area.